Facioscapulohumeral Muscular Dystrophy (FSHD)
4
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
2
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Fulcrum TherapeuticsCAMBRIDGE, MA
3 programs2
1
LosmapimodPhase 31 trial
LosmapimodPhase 21 trial
Losmapimod oral tabletPhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Fulcrum TherapeuticsLosmapimod
Fulcrum TherapeuticsLosmapimod
Fulcrum TherapeuticsLosmapimod oral tablet
aTyr PharmaATYR1940
Clinical Trials (4)
Total enrollment: 8 patients across 4 trials
Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)
Start: Jun 2022Est. completion: Nov 2024
Phase 3Terminated
Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)
Start: Feb 2020Est. completion: Nov 2024
Phase 2Terminated
Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)
Start: Aug 2019Est. completion: Jan 2021
Phase 2Completed
Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy
Start: Mar 2016Est. completion: Dec 20168 patients
Phase 1/2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space